Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Slides:



Advertisements
Similar presentations
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Advertisements

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Integration of Taxanes in the Management of Breast Cancer
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Presented By Raymond Huang at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
1 March 2003 ODAC: DOXIL ®, Ovarian Cancer ODAC Discussion on Accelerated Approval March 12-13, 2003 DOXIL ® (doxorubicin HCl liposome injection) Treatment.
Investigator Meeting SOFT GOCCHI August 16, 2007 BIGBIG.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
Abstract 8504: E4697: Phase III Cooperative Group Study of Yeast Derived GM-CSF vs Placebo as Adjuvant Treatment of Patients with Completely Resected Stage.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Matteo Lambertini, Marcello Ceppi, Francesca Poggio, Fedro A. Peccatori, Hatem A. Azim Jr., Donatella Ugolini, Paolo Pronzato, Sibylle Loibl, Halle C.
Istituto Nazionale per la Ricerca sul Cancro Genoa – Italy
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.
Highlights of the Day-Plenary Session June 1, 2014 Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting.
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.
CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.
Age > 50 Abstract Background Limited data exists regarding outcomes and AT benefit/toxicity in Y pts with stage II and III CC. We examined overall survival.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
INTERGROUP STUDY 0148 BMS CA Effect of TAXOL® (paclitaxel) and Doxorubicin Dose on Disease Free and Overall Survival of Patients with Node Positive.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.
PHARE Trial Results of Subset Analysis Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer Pivot X et al. Proc SABCS 2012;Abstract.
Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.
Presented By Shin Fujita at 2016 ASCO Annual Meeting
Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected Stage 3 Colon Cancer: Cooperative Group Trial N0147 (NCCTG*,
Slamon D et al. SABCS 2009;Abstract 62.
Vose JM et al. Proc ASH 2011;Abstract 661.
A cura di Filippo de Marinis
Alessandra Gennari, MD PhD
Perez EA et al. SABCS 2009;Abstract 80.
Presented By Michael Lee at 2016 ASCO Annual Meeting
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Figure 2. A consort diagram showing the flowchart of the trial
Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Presented By John Bartlett at 2017 ASCO Annual Meeting
Presented By Luca Malorni at 2017 ASCO Annual Meeting
Presented By Amrita Krishnan at 2016 ASCO Annual Meeting
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.
Emma Macdonald Research Assistant / Data Manager
Bergh J et al. SABCS 2009;Abstract 23.
Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011
Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?
Gordon LI et al. Proc ASH 2010;Abstract 415.
ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.
PREGNANCY AND ITS HORMONAL CONTROL.
Martin M et al. Proc SABCS 2012;Abstract S1-7.
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)
RTOG 9704: A Phase III Study of Adjuvant Pre and Post Chemoradiation 5-FU vs. Gemcitabine for Resected Pancreatic Adenocarcinoma A U.S. GI INTERGROUP.
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
Presentation transcript:

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone receptor- negative breast cancer: an international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance) Presented By Halle Moore at 2014 ASCO Annual Meeting

Background Presented By Halle Moore at 2014 ASCO Annual Meeting

Ovarian Protection with LHRH analog Presented By Halle Moore at 2014 ASCO Annual Meeting

POEMS/S0230 Schema Presented By Halle Moore at 2014 ASCO Annual Meeting

POEMS Objectives and Endpoints Presented By Halle Moore at 2014 ASCO Annual Meeting

Goserelin Administration Presented By Halle Moore at 2014 ASCO Annual Meeting

Patient Eligibility Presented By Halle Moore at 2014 ASCO Annual Meeting

Statistical Considerations Presented By Halle Moore at 2014 ASCO Annual Meeting

POEMS Consort Diagram Presented By Halle Moore at 2014 ASCO Annual Meeting

Patients Presented By Halle Moore at 2014 ASCO Annual Meeting

Endocrine Toxicity Presented By Halle Moore at 2014 ASCO Annual Meeting

POEMS Ovarian Failure Presented By Halle Moore at 2014 ASCO Annual Meeting

POEMS Secondary Ovarian Outcomes Presented By Halle Moore at 2014 ASCO Annual Meeting

POEMS Pregnancy Presented By Halle Moore at 2014 ASCO Annual Meeting

POEMS Disease Free Survival Presented By Halle Moore at 2014 ASCO Annual Meeting

POEMS Overall Survival Presented By Halle Moore at 2014 ASCO Annual Meeting

POEMS Presented By Halle Moore at 2014 ASCO Annual Meeting

Conclusions Presented By Halle Moore at 2014 ASCO Annual Meeting

Acknowledgements Presented By Halle Moore at 2014 ASCO Annual Meeting

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.